

## 12-4060: Phospho-Src (Tyr416) (Clone: C4) rabbit mAb

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	SrcY416-C4
<b>Application :</b>	FACS
<b>Reactivity :</b>	Human, Mouse
<b>Conjugate :</b>	Unconjugated
<b>Format :</b>	Purified
<b>Alternative Name :</b>	Proto-oncogene c-Src, pp60c-src, p60-Src, SRC1
<b>Isotype :</b>	Rabbit IgG1k
<b>Immunogen Information :</b>	A synthetic phospho-peptide corresponding to residues surrounding Tyr416 of human phospho Src

### Description

Proto-oncogene tyrosine-protein kinase Src (c-Src, Src), is a non-receptor tyrosine kinase. Src phosphorylates specific tyrosine residues in other proteins and is involved in signal transduction and is important in human tumor development and poor prognosis in cancers. There are nine enzymes (Fyn, Yes, Hck, Lck, Lyn, Blk, Frk, Yrk, and Fgr) closely-related to Src and are collectively called the Src family kinases (SFKs)(1). SFKs represent the largest family of nonreceptor tyrosine kinases and interact directly with receptor tyrosine kinases, G-protein-coupled receptors (GPCRs), steroid receptors, signals transducers, and activators of transcription and molecules involved in cell adhesion and migration. These events lead to proliferation, cell growth, differentiation, cell shape, motility, migration, angiogenesis, and survival. Phosphorylation at Tyr416 in the activation loop of the kinase domain upregulates phospho Src activity, while phosphorylation at Tyr527 in the carboxy-terminal tail decreases activity. Src has been strongly implicated in the development, maintenance, progression, and metastatic spread of several human cancers such as prostate, lung, breast, and colorectal. Structurally, SFKs are highly related to one another and contain conserved structural elements between family members. These elements include the N-terminal Src Homology 4 domain (SH4), the Src Homology 3 domain (SH3), Src Homology 2 domain (SH2), a linker sequence, the tyrosine kinase domain, and the C-terminal tail (2). The N-terminal domain, SH4, serves as a site for myristoylation and targets SFKs to the cytoplasmic membrane. The SH3 domain binds amino acid sequences rich in proline residues (3). This domain is critical for Src activity, intracellular localization, and the recruitment and binding of Src substrates. The SH2 domain binds to short motifs containing phospho-tyrosines. Together, the SH2 and SH3 domains cooperate in regulating SFKs catalytic activity.

### Product Info

<b>Amount :</b>	20 µl / 200 µl
<b>Content :</b>	1X PBS, 0.02% NaN <sub>3</sub> , 50% Glycerol, 0.1% BSA
<b>Storage condition :</b>	Store at -20°C. Avoid repeated freeze and thaw cycles.

### Application Note

1Âµg/mL - 0.001Âµg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml)




Fig-1: Flow cytometric analysis of U937 cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNα IL4 and pervanadate (green) using phospho-Src (Tyr416) antibody SrcY416-C4. at 0.01 µg/mL.




Fig 2 : Flow cytometric analysis of U937 cells secondary antibody only negative control (blue) or untreated (red) treated with IFNα IL4 and pervanadate (green) or treated + blocked with non-phospho-peptide (purple) or treated + blocked with phospho-peptide (brown) using 0.01 µg/mL Phospho-Src (Tyr416) antibody SrcY416-C4.




Fig-3: Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control (orange) or treated with imatinib (red) or with pervanadate (green) using Phospho-Src (Tyr416) antibody SrcY416-C4 at 0.1 µg/mL.